SCHEMBL21074348

SCHEMBL21074348

Cc1ccccc1NC1=NC(=O)/C(=C/c2c[nH]c3ccccc23)S1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCB P05771 1/20 0.44
MAPT P10636 10/20 0.43
KMT2A Q03164 6/20 0.43
ALDH1A1 P00352 6/20 0.43
SMN1; SMN2 Q16637 6/20 0.43
MEN1 O00255 5/20 0.43
GAA P10253 5/20 0.43
PKM P14618 1/20 0.42
KDM4E B2RXH2 3/20 0.40
LMNA P02545 2/20 0.40
HPGD P15428 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
CYP2A6 P11509 1/20 0.39
IMPDH2 P12268 1/20 0.39
ERBB2 P04626 1/20 0.39
NTRK1 P04629 2/20 0.38
TP53 P04637 2/20 0.38
DAPK3 O43293 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29801729 1.00 PRKCB (0.44) PRKCBMAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL19859148 0.93 PTGS1 (0.42) PRKCBMAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL29801526 0.93 PTGS1 (0.42) PRKCBMAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL21074328 0.89 LMNA (0.40) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL21074335 0.87 MAPT (0.45) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL29801609 0.87 ALDH1A1 (0.42) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL19859238 0.87 ALDH1A1 (0.42) MAPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL29801796 0.84 SENP7 (0.48) PRKCBMAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL19859241 0.84 SENP7 (0.48) PRKCBMAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL23361928 0.84 MEN1 (0.39) MAPTKMT2AALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230000839-A1 PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION ZINCURE CORP. (KR) 2023-01-05 US disclosed
EP-3498277-B1 PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION ZINCURE CORP (KR) 2021-10-06 EP disclosed
US-20190167647-A1 PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION ZINCURE CORP. (KR) 2019-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230000839-A1 PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION PRKAB1, PRKAB2, PRKAG1 PRKCB 7/4885MAPT 517/4885KMT2A 2170/4885
US-20190167647-A1 PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION PRKAG1, PRKAB1, PRKAG2 PRKCB 10/4885MAPT 446/4885KMT2A 2053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.